TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02554136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918 + HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918 + HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918 + HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918 + HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918 + HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918 + HGP0816
Study: NCT03682224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Epinephrine
Description: Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
Study: NCT02416414

Intervention type: DEVICE
Intervention: QuantiFERON Monitor Assay
Description: Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.

Intervention type: DEVICE
Intervention: QuantiFERON Monitor Assay
Description: Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.

Intervention type: DEVICE
Intervention: Existing methodology
Description: Assay to measure cell-mediated immune function using existing methodology.

Intervention type: DEVICE
Intervention: Existing methodology
Description: Assay to measure cell-mediated immune function using existing methodology.
Study: NCT00227110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given to match pioglitazone.
Study: NCT00796003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-30979754 20 mg/m2
Description: Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
Study: NCT02045082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal sampling
Description: Slit lamp corneal sampling with a Swab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal sampling
Description: Slit lamp corneal sampling with a Swab
Study: NCT01761370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AHA diet plus exercise with BIB placement
Description: AHA diet plus exercise with BIB placement for 6 months

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: AHA diet plus exercise with sham BIB placement
Description: AHA diet plus exercise with sham BIB placement
Study: NCT01830218

Intervention type: PROCEDURE
Intervention: Obstetric anesthesia and analgesia
Description: All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
Study: NCT00946686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg Tablets (Geneva Pharmaceutical)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
Study: NCT03557424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglucosamine Glucomannan normal dose (Verum)
Description: Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglucosamine Glucomannan high dose (Verum)
Description: Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Study: NCT03576482

Intervention type: OTHER
Intervention: Transport on foot
Description: Patients go to operating room walking with their families and with their normal clothes
Study: NCT04488835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromagnetic field therapy and transcutaneous electrical nerve stimulation
Description: Both groups received conventional physical therapy treatment protocol. Moreover, group (A) has an additional TENS application and group (B) had PEMFS application. TENS and the PEMFT were applied once daily, three times per week for 20 minutes for each session. Assessment performed pre and post intervention using visual analogue scale (VAS) and estimation of the carbamazepine intake (CMI).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromagnetic field therapy and transcutaneous electrical nerve stimulation
Description: Both groups received conventional physical therapy treatment protocol. Moreover, group (A) has an additional TENS application and group (B) had PEMFS application. TENS and the PEMFT were applied once daily, three times per week for 20 minutes for each session. Assessment performed pre and post intervention using visual analogue scale (VAS) and estimation of the carbamazepine intake (CMI).
Study: NCT02023918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegvisomant
Description: Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
Study: NCT02852720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: After the block procedure, 2 ml blood samples will be taken in defined times to determine the plasma blood levels of levobupivacaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Spinal anesthesia in the L3-L4 or L4-L5 interspace with hyperbaric bupivacaine 0,75% 1,4 ml plus 20 ug fentanyl to achieve a bilateral anesthetic level of T4 determined by pinprick.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral vein canulation
Description: An intravenous (18-gauge) catheter will be placed under local anesthesia for co hydration and a second IV catheter for venous sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: TAP blocks will be performed using a ultrasound Sonosite M-Turbo US machine (Sonosite Inc, Washington) with an L38x 10-5 megahertz (MHz), 38-mm broadband linear array probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter
Description: A portable 12-lead Holter (NorthEast Monitoring®, Boston, USA) will record continuously the electrocardiogram (ECG) after the TAP block, for 24 hrs.
Study: NCT01630967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
Study: NCT02726048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplus/Eson
Description: Released product Simplus and Eson masks
Study: NCT04194515

Intervention type: DRUG
Intervention: YH1
Description: YH1 treatment for one month

Intervention type: DRUG
Intervention: metformin
Description: metformin treatment for one month
Study: NCT02512653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cupressus arizonica
Description: Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
Study: NCT03321435

Intervention type: OTHER
Intervention: placenta previa patient
Description: women had placenta previa either major or minor degree
Study: NCT01528995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Interstim II-3058
Description: impulse generator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal bulking injection
Description: Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal bulking injection
Description: Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa
Study: NCT01769625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU
Description: Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU
Description: Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
Study: NCT03321435

Intervention type: OTHER
Intervention: normal women
Description: those women had not placenta previa
Study: NCT00714961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel (SR25990)
Description: plus acetylsalicylic acid (ASA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: plus acetylsalicylic acid (ASA)
Study: NCT00107510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT01769625

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU
Description: Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
Study: NCT01024101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
Study: NCT00379236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUFLEXXA™
Description: EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUFLEXXA™
Description: EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
Study: NCT03175874

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hip bone sampling
Description: Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hip bone sampling
Description: Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hip bone sampling
Description: Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
Study: NCT02699125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
Study: NCT02929628

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Beijing PINS Programming
Description: Using the programming control the Stimulator to change the parameter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beijing PINS Programming
Description: Using the programming control the Stimulator to change the parameter
Study: NCT02376478

Intervention type: DRUG
Intervention: TNF-alpha inhibitors
Description: therapy for at least 6 months

Intervention type: DRUG
Intervention: TNF-alpha inhibitors
Description: therapy for at least 6 months
Study: NCT00107510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT02933268

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High water intake
Description: High water intake aimed at achieving an urine osmolality \< 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ad libitum water intake
Description: Water intake guided by thirst
Study: NCT03394846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test of Existing MI Products
Description: Three widely available MI products (GoNoodle, Take10, ABC for Fitness) will be tested by teachers in their classrooms. Teachers will participate in the study for four weeks (one baseline week, one week for each product).
Study: NCT03881020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine Fluoride 38%
Description: In the intervention group 38% Silver Diamine Fluoride will be applied to the surface of the isolated lesion for a period of 1 minute followed by glass ionomer restoration at the same visit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional atraumatic restorative treatment
Description: In the active comparator group caries will be removed from primary molars using sharp excavators then teeth will be restored using glass ionomer filling material at the same visit.
Study: NCT02816099

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prise de sang

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prise de sang
Study: NCT02452983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate/Biopsy
Study: NCT00151112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positioning and plexus anesthesia
Description: positioning during plexus anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positioning and plexus anesthesia
Description: positioning during plexus anesthesia
Study: NCT03849183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Subcutaneous nitroglycerin injection to increase the first attempt success rate of radial artery cannulation in pediatric patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Subcutaneous normal saline injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
Study: NCT02936180

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HD-TIV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SD-QIV
Study: NCT01152151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Postal reminder letters
Description: Postal reminder letters if adherence is not obtained (up to four)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic reminder letters
Description: Electronic reminder letters if adherence is not obtained (up to four)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reminder letters
Description: up to four reminder letters in september - december 2010
Study: NCT01696968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaire Administration
Description: Undergo questionnaire assessments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo a chest x-ray
Study: NCT01152151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reminder letters
Description: up to four reminder letters in september - december 2010
Study: NCT04229459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100mg/m2 IV on day 1 of induction chemotherapy, 75mg/m2 IV on day 1 and 29 of chemoradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 1000mg/m2/d IV on days 1-5 of induction chemotherapy, 1000mg/m2/d IV on days 1-4 and days 29-32 of chemoradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 1.8 Gy/fraction, 5 days a week for a total of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400mg/m2 IV on day 1 followed by 250mg/m2 IV weekly on induction chemotherapy, 250mg/m2 IV weekly on chemoradiation, 500mg/m2 IV on day 1 of each treatment cycle, every two weeks during immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg IV on day 1 of each treatment cycle, every two weeks during immunotherapy
Study: NCT04607590

Intervention type: OTHER
Intervention: Best Practice
Description: Receive usual care

Intervention type: PROCEDURE
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01364181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil 50mg qd po
Study: NCT01868893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Study: NCT02202863

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red wine grape pomace flour (WGPF)
Description: Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
Study: NCT03929341

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography (CCTA)
Description: Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography (CCTA)
Description: Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Computed Tomography Angiography (CCTA)
Description: Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Computed Tomography Angiography (CCTA)
Description: Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Link
Description: Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Link
Description: Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
Study: NCT00654966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urotensine II
Description: A few drops of the drug will be administered to the skin by iontophoresis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urotensine II
Description: A few drops of the drug will be administered to the skin by iontophoresis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble epoxide hydrolase
Description: A few drops of the drug will be administered to the skin by iontophoresis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soluble epoxide hydrolase
Description: A few drops of the drug will be administered to the skin by iontophoresis.
Study: NCT03472417

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active partial rebreathing device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dummy partial rebreathing device
Study: NCT04607590

Intervention type: PROCEDURE
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02674906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACD-A
Description: use of ACD-A as anticoagulant after blood salvage during cardiac surgery
Study: NCT04607590

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Intervention: Yoga
Description: Participate in yoga sessions

Intervention type: PROCEDURE
Intervention: Yoga
Description: Participate in yoga sessions

Intervention type: PROCEDURE
Intervention: Yoga
Description: Participate in yoga sessions